16 In a study by Karim and colleagues, patients were stratified by age, race, and sex and administered alogliptin 25 mg on day 1 and days 4 8.
An open-label, multicenter, phase II trial assessed the efficacy of intravenous single dose of palonosetron, along with dexamethasone (12 mg on day 1, 8 mg on days 2 and 3), and 3 daily oral doses of aprepitant (125 mg on day 1, 80 mg on days 2 and 3) in patients receiving MEC.
Randomised first-line patients received BI 2536 200 mg on day 1 (n=43) or 60 mg on days 1 3 (n=43) every 21 days.
once daily on days 1 11 and edoxaban 60 mg on day 10; or edoxaban 60 mg once daily on days 1 4 and verapamil 240 mg sustained-release on day 3.
The dexamethasone doses with palonosetron were 20 mg on Day 1 and 16 mg on Days 2 4 (with HEC).
The average wholesale price for a course of aprepitant 125 mg on day 1 and 80 mg on days 2 and 3 is $US312 (Massaro & Lenz 2005).
Control was also improved with a lower dose regimen of aprepitant 40 mg on day 1 and 25 mg on days 2 to 5, but only reached a significant difference from standard therapy during the delayed phase (Table 4).
The treatments were atorvastatin 80 mg (Lipitor, Pfizer) once daily on days 1 8 plus edoxaban 60 mg on day 7; or edoxaban 60 mg on day 1.
In the placebo group, the patients received intravenous administration of placebo, granisetron (40 μg/kg body weight), and dexamethasone phosphate (20 mg) on day 1, and dexamethasone phosphate (8 mg) on days 2 and 3.
Patients were randomly assigned to a continuous intravenous infusion of either hydrocortisone (200 mg/day for 5 days, followed by 100 mg on day 6 and 50 mg on day 7) or placebo.
Patients were randomly assigned to aprepitant 125 mg on day 3 and 80 mg per day on days 4 through 7 or to placebo with initial course and crossover to opposite treatment with the second course.
